
|Articles|April 1, 2003
Psoriasis Drug MIA
San Francisco - The anti-CD40 ligand monoclonal antibody IDEC-131, manufactured by IDEC Pharmaceuticals, was developed to treat autoimmune and inflammatory diseases, such as psoriasis. IDEC-131 targets the CD40 ligand on T cells and regulates the interaction between T cells and B cells.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 STOP-HS Trials Highlight Promise of Oral JAK1 Inhibition for Moderate to Severe Disease
2
Sonelokimab Meets Primary End Point in Phase 3 Psoriatic Arthritis Trial
3
Clinicians Weigh Topical Sequencing and Escalation in Complex Atopic Dermatitis Cases
4
Biologic Therapies in AD and CSU: Progress and the Push for Precision Medicine
5











